Drug delivery device for peripheral artery disease

ABSTRACT

A medical device implantable within a peripheral vessel of the body composed of a bioresorbable polymer is disclosed. The device has a high resistance to fracture, is very flexible, and has a high crush recovery when subjected to crushing, axial, or torsional forces.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates polymeric medical devices, in particular,bioresorbable stents or stent scaffoldings.

2. Description of the State of the Art

This invention relates to radially expandable endoprostheses that areadapted to be implanted in a bodily lumen. An “endoprosthesis”corresponds to an artificial device that is placed inside the body. A“lumen” refers to a cavity of a tubular organ such as a blood vessel. Astent is an example of such an endoprosthesis. Stents are generallycylindrically shaped devices that function to hold open and sometimesexpand a segment of a blood vessel or other anatomical lumen such asurinary tracts and bile ducts. Stents are often used in the treatment ofatherosclerotic stenosis in blood vessels. “Stenosis” refers to anarrowing or constriction of a bodily passage or orifice. In suchtreatments, stents reinforce body vessels and prevent restenosisfollowing angioplasty in the vascular system. “Restenosis” refers to thereoccurrence of stenosis in a blood vessel or heart valve after it hasbeen treated (as by balloon angioplasty, stenting, or valvuloplasty)with apparent success.

Stents are typically composed of a scaffold or scaffolding that includesa pattern or network of interconnecting structural elements or struts,formed from wires, tubes, or sheets of material rolled into acylindrical shape. This scaffolding gets its name because it physicallyholds open and, if desired, expands the wall of the passageway.Typically, stents are capable of being compressed or crimped onto acatheter so that they can be delivered to and deployed at a treatmentsite.

Delivery includes inserting the stent through small lumens using acatheter and transporting it to the treatment site. Deployment includesexpanding the stent to a larger diameter once it is at the desiredlocation. Mechanical intervention with stents has reduced the rate ofrestenosis as compared to balloon angioplasty. Yet, restenosis remains asignificant problem. When restenosis does occur in the stented segment,its treatment can be challenging, as clinical options are more limitedthan for those lesions that were treated solely with a balloon.

Stents are used not only for mechanical intervention but also asvehicles for providing biological therapy. Biological therapy usesmedicated stents to locally administer a therapeutic substance. Amedicated stent may be fabricated by coating the surface of either ametallic or polymeric scaffold with a polymeric carrier that includes anactive or bioactive agent or drug. Polymeric scaffolds may also serve asa carrier of an active agent or drug. An active agent or drug may alsobe included on a scaffold without being incorporated into a polymericcarrier.

The stent are generally made to withstand the structural loads, namelyradial compressive forces, imposed on the scaffold as it supports thewalls of a vessel. Therefore, a stent must possess adequate radialstrength. Radial strength, which is the ability of a stent to resistradial compressive forces, relates to a stent's radial yield strengthand radial stiffness around a circumferential direction of the stent. Astent's “radial yield strength” or “radial strength” (for purposes ofthis application) may be understood as the compressive loading orpressure, which if exceeded, creates a yield stress condition resultingin the stent diameter not returning to its unloaded diameter, i.e.,there is irrecoverable deformation of the stent. See, T. W. Duerig etal., Min Invas Ther & Allied Technol 2000: 9(3/4) 235-246. Stiffness isa measure of the elastic response of a device to an applied load andthus will reflect the effectiveness of the stent in resisting diameterloss due to vessel recoil and other mechanical events. Radial stiffnesscan be defined of a tubular device such as stent as the hoop force perunit length (of the device) required to elastically change its diameter.The inverse or reciprocal of radial stiffness may be referred to as thecompliance. See, T. W. Duerig et al., Min Invas Ther & Allied Technol2000: 9(3/4) 235-246.

When the radial yield strength is exceeded the stent is expected toyield more severely and only a minimal force is required to cause majordeformation. Radial strength is measured either by applying acompressive load to a stent between flat plates or by applying aninwardly-directed radial load to the stent.

Once expanded, the stent must adequately maintain its size and shapethroughout its service life despite the various forces that may come tobear on it, including the cyclic loading induced by the beating heart.For example, a radially directed force may tend to cause a stent torecoil inward. In addition, the stent must possess sufficientflexibility to allow for crimping, expansion, and cyclic loading.

Some treatments with stents require its presence for only a limitedperiod of time. Once treatment is complete, which may include structuraltissue support and/or drug delivery, it may be desirable for the stentto be removed or disappear from the treatment location. One way ofhaving a stent disappear may be by fabricating a stent in whole or inpart from materials that erodes or disintegrate through exposure toconditions within the body. Stents fabricated from biodegradable,bioabsorbable, bioresorbable, and/or bioerodable materials such asbioabsorbable polymers can be designed to completely erode only afterthe clinical need for them has ended.

To treat peripheral vascular disease percutaneously in the lower limbsis a challenge with current technologies. Long term results aresub-optimal due to chronic injury caused by the constant motions of thevessel and the implant as part of every day life situations. To reducethe chronic injury a bioresorbable scaffold for the superficial femoralartery (SFA) and/or the popliteal artery can be used so that thescaffold disappears before it causes any significant long term damage.However, one of the challenges with the development of a femoralscaffold and especially a longer length scaffold (4-25 cm) to be exposedto the distal femoral artery and potentially the popliteal artery is thepresence of fatigue motions that may lead to chronic recoil and strutfractures especially in the superficial femoral artery, prior to theintended bioresorption time especially when implanted in the superficialfemoral artery.

A scaffold in the SFA and/or the popliteal artery is subjected tovarious non-pulsatile forces, such as radial compression, torsion,flexion, and axial extension and compression. These forces place a highdemand on the scaffold mechanical performance and can make the scaffoldmore susceptible to fracture than less demanding anatomies. Stents orscaffolds for peripheral vessels such as the SFA, require a high degreeof crush recovery. The term “crush recovery” is used to describe how thescaffold recovers from a pinch or crush load, while the term “crushresistance” is used to describe the force required to cause a permanentdeformation of a scaffold. It has been believed that a requirement of astent for SFA treatment is a radial strength high enough to maintain avessel at an expanded diameter. A stent with combines such high radialstrength, high crush recovery, and high resistance to fracture is agreat challenge.

A favorable outcome for vascular intervention is the long-termmaintaining of a healthy vessel diameter at the point of intervention.Therefore, an important goal for treatment of the SFA and/or thepopliteal artery is the development of bioabsorbable stent with highcrush recovery and high resistance to fracture that achieves this goal.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference,and as if each said individual publication, patent, or patentapplication was fully set forth, including any figures, herein.

SUMMARY OF THE INVENTION

Embodiments of the invention include a medical device implantable withina peripheral vessel of the body, comprising a cylindrical radiallyexpandable body formed from a polymer formulation comprising abioresorbable elastic material greater than 60 wt % of the body and abioresorbable rigid material less than 40 wt % of the body which formrigid domains dispersed throughout a matrix of the elastic material, andan anti-restenosis drug associated with the body for delivery to thevessel upon implantation of the medical device in the peripheral vessel,wherein the elastic material has a glass transition temperature (Tg)<25deg C. and the rigid polymer or segment has a Tg greater than 37 deg C.,and wherein the body is configured to be expanded from a crimped stateto an expanded state within the peripheral vessel in contact with thevessel wall.

Embodiments of the invention include a medical device implantable withina peripheral vessel of the body, comprising a cylindrical radiallyexpandable body formed from a polymer formulation comprising across-linked elastic material, and an anti-restenosis drug associatedwith the body for delivery to the vessel upon implantation of themedical device in the peripheral vessel, wherein the elastic materialhas a glass transition temperature (Tg)<25 deg C. and the rigid polymeror segment has a Tg greater than 37 deg C., and wherein the body isconfigured to be expanded from a crimped state to an expanded statewithin the peripheral vessel in contact with the vessel wall.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts a view of an exemplary scaffold.

DETAILED DESCRIPTION OF THE INVENTION

In many treatment applications using stents, such as coronaryintervention, stents expand and hold open narrowed portions of bloodvessels. To achieve this, the stent must possess a radial strength in anexpanded state that is sufficiently high and sustainable to maintain theexpanded vessel size for a period of weeks or months. This generallyrequires a high strength, rigid material. In the case of bioresorbablepolymer stents, bioresorbable polymers that are stiff and rigid havebeen proposed and used in stents for coronary intervention. Suchpolymers are stiff or rigid under physiological conditions within ahuman body. These polymers tend to be semicrystalline polymers that havea glass transition temperature (Tg) sufficiently above human bodytemperature (approximately 37° C.) that the polymer is stiff or rigid atthese conditions. Poly(L-lactide) (PLLA) is an example of such amaterial which remains stiff and rigid at human body temperature whichfacilitates the ability of a stent to maintain a lumen at or near adeployed diameter.

Such polymers, however, may have a tendency to fail with a brittlefracture mechanism so that fractures develop at a relative low strainmeaning they have a relatively low elongation at break. Therefore, astent made from such high strength, rigid polymers may be susceptible tofracture if subjected to sufficiently high strains repeatedly. Forcoronary application, due to the small cyclic deformation of vessel, therisk of fracture may be of little or no concern.

However, for peripheral application, due to the constant movement ofleg, the requirement of flexibility or resistance to fracture and crushrecovery of the device is much higher than the requirement of itsstiffness. Specifically, the ability to maintain long term structuralintegrity and eliminate the probability of fatigue fracture inlarge-amplitude deformations becomes more important than maintainingacute radial strength and radial stiffness.

An alternative to a drug-delivery stent is an anti-restenosis drugcoated balloon (DCB). The DCB attempts to address the elastic recoil ofthe stretched arterial wall following conventional angioplasty with adrug-free balloon. The recoil of the arterial wall can undo much of whatwas accomplished by balloon angioplasty which results in restenosis, there-clogging of the treated artery. In DCB treatment, a coatingcontaining a drug is formed on the exterior of a balloon. When theballoon is inflated at a target site within a vessel, and the balloonwalls contact the vessel walls, the drug is released to the vesselwalls. In practice, the majority of the drug is released from thesurface of the balloon during its inflation, which may be a few secondsto a few minutes. Like angioplasty, the balloon is then removed, leavingthe treated vessel wall with no mechanical support.

Recent clinical studies show that vascular intervention with a drugcoated balloon (DCB) may be effective for the treatment of peripheralvascular disease. In particular, the SFA of patients were treated with aPaclitaxel-coated balloon. Micari A, et al. J Am Coll Cardiol Intv.2012; 5:331-338. After 1 year of treatment, more than 70% lumen patencyremained. This was achieved in spite of the short time drug releaseprovided by the DCB and lack of vessel support after balloonintervention. One hypothesis that can be drawn from this study is thatthe results can be further improved by long term drug release after theDCB is removed and the residual drug remaining at the site has beenreleased.

Based on the success of DCB and desire to eliminate the susceptibilityof a device to fracture of a high strength, rigid stent, the inventorspropose an implantable bioresorbable device with a longer time drugrelease, having good flexibility, good crush recovery, and high fatiguefracture resistance. The proposed device, however, does not necessarilyhave sufficient radial strength to prevent the diameter change ascommercially available drug eluting stents. The proposed device may havesufficient radial strength to provide limited lumen support.

Embodiments of the present invention are a cylindrical, radiallyexpandable device for implantation in peripheral blood vessels, such asthe SFA, that incorporates drug(s) for treatment of restenosis. Thedevice has a high resistance to fracture, low radial stiffness, and highcrush recovery. The device may also have a very low radial strength. Thedrugs can include antiproliferative drugs, anti-inflammatory drugs, andothers disclosed herein.

In some embodiments, the device may also have relatively low radialstrength that is insufficient to provide mechanical support to vesselwalls. For example, if the vessel wall has a tendency to move inwardafter implantation, the device may not have sufficient outward force toprevent the inward movement. In such a case, the inward pressure of thevessel exceeds the radial strength of the device and the device exhibitsirrecoverable inward radial deformation. In certain embodiments, theoutward force applied by the device may only be sufficient to maintainits position in contact with the vessel walls. Therefore, in suchembodiments, the device acts as an elastic lining on the vessel wall forproviding sustained drug delivery to the vessel wall.

In other embodiments, the device may have a radial strength that is highenough to provide some mechanical support to the vessel walls. In thiscase, the device can prevent or reduce the degree of inward movement ofthe vessel walls since the radial strength exceeds the inward force orpressure of the vessel walls.

However, since the radial stiffness of the device is relatively low, theinward force of the vessel walls may result in a decrease in diameter ofthe vessel even when the radial strength of the device is higher thanthe inward pressure of the vessel walls. In this case, the inwarddeformation of the device is recoverable since it is elastic deformationinward. Due to the recoverable deformation, the device exhibits achronic outward force at the reduced diameter.

The material properties of the device material and the device propertiessuch as radial strength and radial stiffness will change as the devicedegrades after implantation. However, as the device decrease, the devicewill become embedded in endothelial cells. Therefore, as the propertiesdeteriorate and the device losses mechanical integrity and mass thedevice will not present danger embolic events.

In certain embodiments, the device may be designed such that its initialradial stiffness or compliance is close to, the same, or less than theradial stiffness of the vessel into which is it implanted. For example,the device may have compliance 70 to 90% of the vessel or 100 to 130% ofa vessel. The vessel compliance can be taken to be the compliance of ahealthy vessel at site of implantation.

In some embodiments, the device is mounted over a delivery balloon at areduced profile and may be delivered to an implant site and expanded bythe balloon to an expanded diameter. The implant site may be a narrowedportion of the artery and the narrowed portion may be expanded by theexpansion of the device. The primary purpose of the implanted device isto provide sustained drug delivery and may provide no mechanical supportor patency to the lumen at the implant site. Thus, upon delivery, thedevice and removal of the balloon, the device may not prevent anyelastic recoil of the vessel walls. The post-delivery diameter of thevessel may be due entirely to the natural strength of the vessel walls.

The device may be made partially or completely from a biodegradable,bioresorbable, or bioabsorbable polymer. The device may include somebiostable polymer. The device may be configured to eventually completelyabsorb from an implant site. The device may provide drug delivery onceimplanted, provide no mechanical support to the vessel, and thengradually completely absorb away. The device may be configured tocompletely erode away within 6 months, 6 to 12 months, 12 to 18 months,18 months to 2 years, or greater than 2 years.

A completely bioresorbable device may still include somenonbiodegradable elements such as radiopaque markers or particulateadditives. A polymer for use in fabricating stent can be biostable,bioresorbable, bioabsorbable, biodegradable, or bioerodable. Biostablerefers to polymers that are not biodegradable. The terms biodegradable,bioresorbable, bioabsorbable, and bioerodable are used interchangeablyand refer to polymers that are capable of being completely degradedand/or eroded into different degrees of molecular levels when exposed tobodily fluids such as blood and can be gradually resorbed, absorbed,and/or eliminated by the body. The processes of breaking down andabsorption of the polymer can be caused by, for example, hydrolysis andmetabolic processes.

A blood vessel may have a tendency to decrease in diameter or recoilright after implantation (i.e., less than about 30 minutespost-implantation) as well as over a period of days, weeks, or months.Once implanted, the device may not have radial strength sufficient toreduce or prevent the immediate or long-term recoil.

In some embodiments, the radial strength of the device is relativelylow. The radial strength of the device immediately after expansion to anintended deployment diameter in a vessel may at most be the radialpressure required for the device to maintain contact with vessel wall.The radial strength may be the less than the minimum pressure to preventsmooth muscle movement. The radial strength may be less than 150 mm Hg,100 to 150 mm Hg, 1 to 10 mm Hg, or less than 100 mm Hg. The radialstrength can be based on a diameter of an as-fabricated device prior tocrimping and expansion or a device after it has been crimped andexpanded to an intended deployment diameter.

In other embodiments, the radial strength can be high enough to providemechanical support to a vessel and prevent or reduce a decrease in thediameter of the vessel or to high enough to so that the vessel does notcause irrecoverable deformation. In such embodiments, the radialstrength can be greater than 200 mm Hg, 200-300 mm Hg, or higher than300 mm Hg.

The body of the device has a high resistance to fracture that may resultfrom forces on the device imposed during crimping and deployment andafter deployment. The body of the device may be made of mostly orcompletely of a bioabsorbable polymer material or formulation. Amajority of the polymer formulation may include a high toughness,elastic material which is an elastic polymer or polymer segments orblocks. The body may be composed of at least 60 wt % of the elasticmaterial in the form of segments, blocks, polymer, or a combinationthereof.

The elastic material of the formulation may be characterized by severalproperties and may have one or any combination such properties. Theelastic material may have an elongation at break greater than 30%, 50%,80%, 100%, 500%, or above 500%. The elastic polymer material may be aflexible material with a modulus of elasticity less than 1.5 GPa, 1 GPa,or 0.5 GPa, or can be 0.5 GPa to 1 GPa at 25 deg C., 37 deg C., or in arange of 25 to 37 deg C. Additionally, the elastic material may have aTg less than body temperature or 37 deg C., less than 25 deg C., or lessthan 0 deg C.

The polymer formulation of the device which may make up all or a portionof a device body, may also be characterized by several properties andmay have one or any combination such properties. The polymer formulationmay have an elongation at break greater than 30%, 50%, 80%, 100%, 500%,or above 500%. The polymer formation may have a modulus of elasticityless than 1.5 GPa, 1 GPa, or 0.5 GPa or 0.5 to 1 GPa at 25 deg C., 37deg C., or in a range of 25 to 37 deg C.

The device may be made of a material with the elastic material as amatrix and rigid material (rigid polymers or segments) that form rigiddomains dispersed throughout the matrix which act as physicalcross-linking net points. The elastic matrix provides high flexibilityand good fatigue fracture resistance. The rigid domains act as physicalcross-linking net points to ensure high crush recovery. The rigiddomains may also provide a small amount lumen support. The matrix mayhave the Tg of the elastic material and the rigid domains may have theTg of the rigid material.

Rigid domains may include or be composed of rigid polymers or segmentssuch as PLLA and polyglycolide. The rigid domains may have a size (i.e.,diameter) of 1 to 5 microns, or 0.1 to 1 microns.

Examples of biodegradable elastic polymers or segments include but arenot limited to poly(4-hydroxybutyrate) (P4HB), polycaprolactone (PCL),poly(trimethylene carbonate) (PTMC), poly(butylene succinate) (PBS),poly(p-dioxanone) (PDO). The device material can include blends ofelastic polymers with rigid polymers or other elastic polymers,copolymers (block, random or alternating) of elastic polymers with rigidpolymers or other elastic polymers, or any combination thereof.

The rigid polymers or segments may be characterized by severalproperties and may have one or any combination such properties. Therigid polymers or segments may have an elongation at break less than20%, 10%, 5%, or 3%. The rigid polymers or segments may have a modulusof elasticity greater than 3 GPa, 5 GPa, or 7 GPa. Additionally, therigid polymers or segments may have a Tg greater than body temperatureor 37 deg C., or greater than 10 or greater than 20 deg C. above humanbody temperature or 37 deg C. The rigid polymers or segments may haveone or any combination of such properties.

Other rigid bioresorbable polymers or segments include poly(D-lactide)(PDLA), and poly(L-lactide-co-glycolide) (PLGA). The PLGA includes thosehaving a mole % of (LA:GA) of 85:15 (or a range of 82:18 to 88:12), 95:5(or a range of 93:7 to 97:3), or commercially available PLGA productsidentified being 85:15 or 95:5 PLGA.

Drug delivery from the device can be provided from a coating on asurface of the body of the device. The coating may be in the form a neatdrug. Alternatively, the coating includes a polymer matrix with the drugmixed or dissolved in the polymer. The polymer matrix can bebioresorbable. Suitable polymers for the drug delivery polymer caninclude poly(DL-Lactide), polycaprolactone, poly(L-lactide),polyglycolide, or poly(glycolide-co-caprolactone).

The coating can be formed by mixing the polymer and the drug in asolvent and applying the solution to the surface of the device. The drugrelease rate may be controlled by adjusting the ratio of drug andpolymeric coating material. The drug may be released from the coatingover a period of one to two weeks, up to one month, or up to threemonths after implantation. Thickness of the coating on the device bodymay 1 to 20 microns, 1 to 2 microns, 1 to 5 microns, 2 to 5 microns, 3to 5 microns, 5 to 10 microns, or 10 to 20 microns. In some embodiments,the body of the device includes a drug release coating and the body isfree of drug, aside from any incidental migration of drug into the bodyfrom the coating.

Alternatively or additionally, the drug can also be embedded ordispersed into the body of device, and be slowly released up to months(e.g., three months after implantation) and while the device isdegrading. In this case, the drug can be included with the polymer whenthe tube is formed that is used to form the device. For example, thedrug can be included in the polymer melt during extrusion or injectionmolding or in a solution when the tube is formed from dipping orspraying or casting.

There are several embodiments of the device material or polymerformulation that includes the elastic polymer or segments and the rigidpolymer or segments.

A first set of embodiments is a polymer blend of an elastic polymer asmatrix and copolymer containing rigid segments and elastic segments. Theblend can include greater than 60 wt % elastic polymer and less than 40wt % of the copolymer. The elastic segments of the copolymer act asanchor chains to ensure the compatibility of the copolymer and elasticmatrix material, while the rigid segment forming rigid domains that actsas physical cross-linking net points.

The elastic material of the blend can include PCL, PTMC, PDO, and P4HBwhile the copolymer can be PLLA-PCL, PLLA-PTMC, PLLA-PDO, or PGA-PCLcopolymer, where the elastic polymer of the matrix is paired with thecopolymer having the elastic polymer as a segment. The copolymer can beeither block copolymer or random copolymer. At least some rigid chainsshould be long enough to form physical crosslinks together.

In this first set of embodiments, the molecular weight (MW) of theelastic material may be greater than 50 kDa, for example, 50 to 100 kDa.The MW of the copolymer may be greater than 50 kDa, for example, 50 to100 kDa. The MW of rigid and elastic segments of copolymer may both beabove 20 kDa, for example, 20 to 80 kDa.

A preferred combination of elastic material and copolymer may be 70 wt %and 30 wt %, respectively, with a range of 60 to 80 wt % and 20 to 40 wt%, respectively. The composition of rigid and elastic segments ofcopolymer may each be less than 20 wt % of the copolymer.

A second set of embodiments is a polymer blend of bioresorbable elasticpolymer as matrix (more than 60 wt %, or 60 to 80 wt %) and rigidpolymer forming rigid domains that act as physical cross-linking netpoints (less than 40 wt % or 20 to 40 wt %). The blend can furtherinclude a block copolymer (less than 5 wt %, or 3 to 5 wt %) containingrigid segments and elastic segments as compatibilizer. The copolymer canact as anchor chains to ensure the compatibility of the elastic matrixmaterial and rigid domains. The rigid material acts as physicalcross-linking net points and its crystallinity increased thoughannealing or deformation. The elastic material of the blend can be PCL,PTMC, PDO, P4HB, while the rigid material can be PLLA or PGA. Thecopolymer can be PLLA-PCL, PLLA-PTMC, PLLA-PDO or PGA-PCL blockcopolymer, where the copolymer is paired with a blend corresponding tothe segments of the copolymer. The blends can be prepared by meltblending or solution blending.

In this second set of embodiments, the MW of the elastic material may begreater than 50 kDa, for example, 50 to 100 kDa. The MW of the rigidmaterial may be greater than 50 kDa, for example, 50 to 100 kDa. The MWof the copolymer may be greater than 50 kDa, for example, 50 to 100 kDa.The MW of rigid and elastic segments of copolymer may both be above 20kDa, for example, 20 80 kDa.

A preferred combination of elastic material, rigid material, andcopolymer may be 80 wt %, 17 wt %, and 3 wt %, respectively.

A third set of embodiments is a polymer blend of a bioresorbable elasticcopolymer material as matrix (more than 80 wt %, or 80 to 90 wt %), andrigid material forming rigid domains that act as physical cross-linkingnet points (less than 20 wt %, or 10 to 20 wt %). The rigid segments ofthe elastic copolymer act as anchor chains to ensure the compatibilityof the copolymer matrix and rigid material. The rigid material can bePLLA, PGA, while the copolymer can be PCL-PLLA, PTMC-PLLA, PDO-PLLA orPCL-PGA copolymer, where the rigid polymer is paired with an elasticcopolymer with the same rigid polymer component. The elastic copolymercan be either block copolymer or random copolymer.

In the context of a random copolymer, “segment” can refer to a singleunit derived from a polymer or several chemical bonded units derivedfrom monomer units. In the context of a block copolymer, “block” canrefer to several chemically bonded derived from monomer units having aMW of at least 50 kDa. The elastic segment in the copolymer matrix maybe higher than 80 wt %.

In this third set of embodiments, the MW of the elastic copolymer may begreater than 50 kDa, for example, 50 to 100 kDa. The MW of the rigidmaterial may be greater than 50 kDa, for example, 50 to 100 kDa. The MWof rigid and elastic segments of elastic copolymer may both be above 20kDa, for example, 20 to 80 kDa.

A fourth set of embodiments is a bioresorbable block copolymer with morethan 60 wt % elastic segment content and less than 40 wt % crystallizedrigid segment forming domains that act as physical cross-linking netpoints. The copolymer can be, for example, PCL-PLLA, PTMC-PLLA, PDO-PLLAor PCL-PGA copolymer. To ensure that the rigid segment works as physicalcross-linking net points, the molecular weight of rigid segment in eachblock copolymer chain should be higher than its entanglement molecularweight, and preferred to be more than two times higher than itsentanglement molecular weight. For PCL-PLLA or PDO-PLLA copolymer, themolecular weight of PLLA segment is preferred to be at least more than20 kDa. After blending, a tube is formed by, for example, extrusion orsolution casting.

In this fourth set of embodiments, the MW of the block copolymer may begreater than 80 kDa, for example, 80 to 100 kDa. The MW of the elasticsegment may be above 50 kDa, for example, 50 to 70 kDa and the MW ofrigid segment may be above 30 kDa, for example, 30 to 50 kDa.

The above polymer blends can be prepared by melt blending or solutionblending. After making the device material, a tube is formed byextrusion, solution casting, dipping, or injection molding.

A fifth set of embodiments is a polymer formulation that includes acrosslinked bioresorbable elastic polymer. A device can be formed froman elastic polymer with reactive end groups or side groups that can formcrosslinks upon exposure to heat or radiation. Alternatively, a devicecan be formed from an elastic polymer including a crosslinking agentthat can form crosslinks upon exposure to heat or radiation.

To fabricate the device, a tube may be formed from the elastic polymerby extrusion or solution casting and then is cut by a laser to form apattern in the tube. After that, crosslinking is initiated high energye-beam, or by UV light or by heat to form the chemical cross-linking netpoints. The radiation or heat initiates reaction of the reactiveend/side groups with each or initiates the crosslinking by thecrosslinking agent. Alternatively, the crosslinking step can beperformed before laser cutting. After crosslinking, the tube may belaser cut.

The types of polymers that can be crosslinked in this manner includePCL, PTMC, PDO or copolymers such as PCL-PLLA or PCL-PGA. The reactiveend/side group includes di-iscocynate or di-acrylate groups. Exemplarycrosslinking agents include triallyl isocyanurate (TALC), trimethallyisocyanurate (TMAIC), and trimethylolpropane triacrylate (TMPTA).Exemplary methods of making a crosslinked bioresorbable aliphaticpolyester are disclosed in US2010-0262223.

The rigid domains may be semicrystalline with a crystallinity of 10 to50%, 10 to 20%, 20 to 30%, 30 to 40%, 40 to 50%, or greater than 50%.After forming a tube, the crystallinity of the domains may be increasedby annealing the tube at a temperature above the Tg of the rigid polymeror segments. Additionally or alternatively, the tube may be radiallyexpanded at a temperature above the Tg of the rigid polymer or segmentsto increase the crystallinity.

A formed tube may be free or substantially free of holes between theinterior and exterior surface. The device can be fabricated from theformed tube with laser cutting which forms a tubular device withstructural elements and gaps in the tube wall between the inner andouter surface formed by laser cutting.

The final device can be balloon expandable or self expandable. In thecase of a balloon expandable device, the geometry of the device can bean open-cell structure similar to the stent patterns disclosed herein orclose cell structure, each formed through laser cutting the tube. In aballoon expandable device, when the device is crimped from a fabricateddiameter to a crimped or delivery diameter onto a balloon, structuralelements plastically deform. Aside from incidental recoil outward, thedevice retains a crimped diameter without an inward force on the crimpeddevice due to the plastically deformed structural elements. When thedevice is expanded by the balloon, the structural elements plasticallydeform. The device is expanded to an intended expansion or deploymentdiameter and retains the intended expansion diameter or a diameterslightly less due to incidental recoil inward due to inward pressurefrom the vessel, stress relaxation, or both. At the final expandeddiameter, the device does not exert any chronic outward force, which isa radial outward force exerted by the device in excess of the radialinward force exerted by the vessel on device.

In the case of a self expandable device, when the device is crimped froma fabricated diameter to a crimped or delivery diameter on a balloon,structural elements deform elastically. Therefore, to retain the deviceat the crimped diameter, the device is restrained in some manner with aninward force, for example with a sheath or a band. The crimped device isexpanded to an intended expansion or deployment diameter by removing theinward restraining force which allows the device to self-expand to theintended deployment diameter. The structural elements deform elasticallyas the device self-expands. If the final expansion diameter is the sameas the fabricated diameter, the device does not exert any chronicoutward force. If the final expansion diameter is less than thefabricated diameter, the device does exert a chronic outward force. Thegeometry of the self-expandable device can be a helical constructincluding a set of spiral coils through laser cutting, or it can also belike a coil through weaving the extruded and annealed fibers.

The geometric structure of the device is not limited to any particularstent pattern or geometry. The device can have the form of a tubularscaffold structure that is composed of a plurality of ring struts andlink struts. The ring struts form a plurality of cylindrical ringsarranged about the cylindrical axis. The rings are connected by the linkstruts. The scaffold comprises an open framework of struts and linksthat define a generally tubular body with gaps in the body defined bythe rings and struts.

A thin-walled cylindrical tube of may be formed into this open frameworkof struts and links described by a laser cutting device that cuts such apattern into the thin-walled tube that may initially have no gaps in thetube wall. The scaffold may also be fabricated from a sheet by rollingand bonding the sheet to form the tube.

FIG. 1 depicts a view of an exemplary scaffold 100 which includes apattern or network of interconnecting structural elements 105. FIG. 1illustrates features that are typical to many stent patterns includingcylindrical rings 107 connected by linking elements 110. The cylindricalrings are load bearing in that they provide radially directed force inresponse to an inward force on the scaffold. The linking elementsgenerally function to hold the cylindrical rings together. Exemplaryscaffolds are disclosed in US2008/0275537, US2011/0190872, andUS2011/0190871.

The device may have lengths of between 12 and 18 mm, 18 and 36 mm, 36and 40 mm or even between 40 and 200 mm as fabricated or when implantedin the superficial femoral artery, as an example. The device may have apre-crimping or as-fabricated diameter of between 5-10 mm, 6-8 mm, orany value between and including these endpoints. The device for may havea wall thickness of about 100 to 150 microns, 150 to 200 microns, 200 to250 microns, 250 to 300 microns, 300 to 350 microns, 350 to 400 microns,or greater than 400 microns.

The device may be configured for being deployed by a non-compliant orsemi-compliant balloon from about a 1.8 to 2.2 mm diameter (e.g., 2 mm)crimped profile. Exemplary balloon sizes include 5 mm, 5.5 mm, 6 mm, 6.5mm, 7 mm, or 8 mm, where the balloon size refers to a nominal inflateddiameter of the balloon. The device may be deployed to a diameter ofbetween 4 mm and 10 mm, 7 to 9 mm, or any value between and includingthe endpoints. Embodiments of the invention include the device in acrimped diameter over and in contact with a deflated catheter balloon.

The intended deployment diameter may correspond to, but is not limitedto, the nominal deployment diameter of a catheter balloon which isconfigured to expand the scaffold. A device scaffold may be laser cutfrom a tube (i.e., a pre-cut tube) that is less than an intendeddeployment diameter. In this case, pre-cut tube diameter may be 0.7 to 1times the intended deployment diameter or any value in between andincluding the endpoints.

A device scaffold may be laser cut from a tube (i.e., a pre-cut tube)that is greater than an intended deployment diameter. In this case, thepre-cut tube diameter may be 1 to 1.5 times the intended deploymentdiameter, or any value in between and including the endpoints.

The device of the present invention has high crush recovery and crushresistance. Crush recovery describes the recovery of a tubular devicesubjected to a pinch or crush load. Specifically, the crush recovery canbe described as the percent recovery to the device pre-crush shape ordiameter from a certain percent crushed shape or diameter. Crushresistance is the minimum force required to cause a permanentdeformation of a scaffold. The crush recovery and crush resistance canbe based on a pre-crush shape or diameter of an as-fabricated deviceprior to crimping and expansion or a device after it has been crimpedand expanded to an intended deployment diameter. The crush recovery ofthe device can be such that the device attains greater than about 80% or90% of its diameter after being crushed to at least 50% of its pre-crushdiameter.

The steps for fabrication of the device can include the following steps:

(1) forming a polymeric tube using extrusion,

(2) radially deforming the formed tube,

(3) forming a stent scaffolding from the deformed tube by lasermachining a stent pattern in the deformed tube with laser cutting,

(4) optionally forming a therapeutic coating over the scaffolding,

(5) crimping the stent over a delivery balloon, and

(6) sterilization with election-beam (E-Beam) radiation.

In the extrusion step, a polymer is processed in an extruder above themelting temperature of the copolymer. In step (2) above, the extrudedtube may be radially deformed to increase the radial strength of thetube, and thus, the finished stent and also to increase crystallinity.Detailed discussion of the manufacturing process of a bioabsorbablestent can be found elsewhere, e.g., U.S. Patent Publication Nos.20070283552 and 20120073733.

The device body may include or may be coated with one or moretherapeutic agents, including an antiproliferative, anti-inflammatory orimmune modulating, anti-migratory, anti-thrombotic or other pro-healingagent or a combination thereof. The anti-proliferative agent can be anatural proteineous agent such as a cytotoxin or a synthetic molecule orother substances such as actinomycin D, or derivatives and analogsthereof (manufactured by Sigma-Aldrich 1001 West Saint Paul Avenue,Milwaukee, Wis. 53233; or COSMEGEN available from Merck) (synonyms ofactinomycin D include dactinomycin, actinomycin IV, actinomycin I1,actinomycin X1, and actinomycin C1), all taxoids such as taxols,docetaxel, and paclitaxel, paclitaxel derivatives, all olimus drugs suchas macrolide antibiotics, rapamycin, everolimus, structural derivativesand functional analogues of rapamycin, structural derivatives andfunctional analogues of everolimus, FKBP-12 mediated mTOR inhibitors,biolimus, perfenidone, prodrugs thereof, co-drugs thereof, andcombinations thereof. Representative rapamycin derivatives include40-O-(3-hydroxy)propyl-rapamycin,40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, or 40-O-tetrazole-rapamycin,40-epi-(N1-tetrazolyl)-rapamycin (ABT-578 manufactured by AbbottLaboratories, Abbott Park, Ill.), prodrugs thereof, co-drugs thereof,and combinations thereof.

The anti-inflammatory agent can be a steroidal anti-inflammatory agent,a nonsteroidal anti-inflammatory agent, or a combination thereof. Insome embodiments, anti-inflammatory drugs include, but are not limitedto, alclofenac, alclometasone dipropionate, algestone acetonide, alphaamylase, amcinafal, amcinafide, amfenac sodium, amiprilosehydrochloride, anakinra, anirolac, anitrazafen, apazone, balsalazidedisodium, bendazac, benoxaprofen, benzydamine hydrochloride, bromelains,broperamole, budesonide, carprofen, cicloprofen, cintazone, cliprofen,clobetasol propionate, clobetasone butyrate, clopirac, cloticasonepropionate, cormethasone acetate, cortodoxone, deflazacort, desonide,desoximetasone, dexamethasone dipropionate, diclofenac potassium,diclofenac sodium, diflorasone diacetate, diflumidone sodium,diflunisal, difluprednate, diftalone, dimethyl sulfoxide, drocinonide,endrysone, enlimomab, enolicam sodium, epirizole, etodolac, etofenamate,felbinac, fenamole, fenbufen, fenclofenac, fenclorac, fendosal,fenpipalone, fentiazac, flazalone, fluazacort, flufenamic acid,flumizole, flunisolide acetate, flunixin, flunixin meglumine, fluocortinbutyl, fluorometholone acetate, fluquazone, flurbiprofen, fluretofen,fluticasone propionate, furaprofen, furobufen, halcinonide, halobetasolpropionate, halopredone acetate, ibufenac, ibuprofen, ibuprofenaluminum, ibuprofen piconol, ilonidap, indomethacin, indomethacinsodium, indoprofen, indoxole, intrazole, isoflupredone acetate,isoxepac, isoxicam, ketoprofen, lofemizole hydrochloride, lomoxicam,loteprednol etabonate, meclofenamate sodium, meclofenamic acid,meclorisone dibutyrate, mefenamic acid, mesalamine, meseclazone,methylprednisolone suleptanate, momiflumate, nabumetone, naproxen,naproxen sodium, naproxol, nimazone, olsalazine sodium, orgotein,orpanoxin, oxaprozin, oxyphenbutazone, paranyline hydrochloride,pentosan polysulfate sodium, phenbutazone sodium glycerate, pirfenidone,piroxicam, piroxicam cinnamate, piroxicam olamine, pirprofen,prednazate, prifelone, prodolic acid, proquazone, proxazole, proxazolecitrate, rimexolone, romazarit, salcolex, salnacedin, salsalate,sanguinarium chloride, seclazone, sermetacin, sudoxicam, sulindac,suprofen, talmetacin, talniflumate, talosalate, tebufelone, tenidap,tenidap sodium, tenoxicam, tesicam, tesimide, tetrydamine, tiopinac,tixocortol pivalate, tolmetin, tolmetin sodium, triclonide,triflumidate, zidometacin, zomepirac sodium, aspirin (acetylsalicylicacid), salicylic acid, corticosteroids, glucocorticoids, tacrolimus,pimecorlimus, prodrugs thereof, co-drugs thereof, and combinationsthereof.

These agents can also have anti-proliferative and/or anti-inflammatoryproperties or can have other properties such as antineoplastic,antiplatelet, anti-coagulant, anti-fibrin, antithrombonic, antimitotic,antibiotic, antiallergic, antioxidant as well as cystostatic agents.Examples of suitable therapeutic and prophylactic agents includesynthetic inorganic and organic compounds, proteins and peptides,polysaccharides and other sugars, lipids, and DNA and RNA nucleic acidsequences having therapeutic, prophylactic or diagnostic activities.Nucleic acid sequences include genes, antisense molecules which bind tocomplementary DNA to inhibit transcription, and ribozymes. Some otherexamples of other bioactive agents include antibodies, receptor ligands,enzymes, adhesion peptides, blood clotting factors, inhibitors or clotdissolving agents such as streptokinase and tissue plasminogenactivator, antigens for immunization, hormones and growth factors,oligonucleotides such as antisense oligonucleotides and ribozymes andretroviral vectors for use in gene therapy. Examples of antineoplasticsand/or antimitotics include methotrexate, azathioprine, vincristine,vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin®from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin®from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of suchantiplatelets, anticoagulants, antifibrin, and antithrombins includesodium heparin, low molecular weight heparins, heparinoids, hirudin,argatroban, forskolin, vapiprost, prostacyclin and prostacyclinanalogues, dextran, D-phe-pro-arg-chloromethylketone (syntheticantithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membranereceptor antagonist antibody, recombinant hirudin, thrombin inhibitorssuch as Angiomax a (Biogen, Inc., Cambridge, Mass.), calcium channelblockers (such as nifedipine), colchicine, fibroblast growth factor(FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists,lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol loweringdrug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station,N.J.), monoclonal antibodies (such as those specific forPlatelet-Derived Growth Factor (PDGF) receptors), nitroprusside,phosphodiesterase inhibitors, prostaglandin inhibitors, suramin,serotonin blockers, steroids, thioprotease inhibitors,triazolopyrimidine (a PDGF antagonist), nitric oxide or nitric oxidedonors, super oxide dismutases, super oxide dismutase mimetic,4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), estradiol,anticancer agents, dietary supplements such as various vitamins, and acombination thereof. Examples of such cytostatic substance includeangiopeptin, angiotensin converting enzyme inhibitors such as captopril(e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford,Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® fromMerck & Co., Inc., Whitehouse Station, N.J.). An example of anantiallergic agent is permirolast potassium. Other therapeuticsubstances or agents which may be appropriate include alpha-interferon,and genetically engineered epithelial cells. The foregoing substancesare listed by way of example and are not meant to be limiting. Otheractive agents which are currently available or that may be developed inthe future are equally applicable.

“Molecular weight refers to either number average molecular weight (Mn)or weight average molecular weight (Mw). References to molecular weight(MW) herein refer to either Mn or Mw, unless otherwise specified.

“Semi-crystalline polymer” refers to a polymer that has or can haveregions of crystalline molecular structure and amorphous regions. Thecrystalline regions may be referred to as crystallites or spheruliteswhich can be dispersed or embedded within amorphous regions.

The “glass transition temperature,” Tg, is the temperature at which theamorphous domains of a polymer change from a brittle vitreous state to asolid deformable or ductile state at atmospheric pressure. In otherwords, the Tg corresponds to the temperature where the onset ofsegmental motion in the chains of the polymer occurs. When an amorphousor semi-crystalline polymer is exposed to an increasing temperature, thecoefficient of expansion and the heat capacity of the polymer bothincrease as the temperature is raised, indicating increased molecularmotion. As the temperature is increased, the heat capacity increases.The increasing heat capacity corresponds to an increase in heatdissipation through movement. Tg of a given polymer can be dependent onthe heating rate and can be influenced by the thermal history of thepolymer as well as its degree of crystallinity. Furthermore, thechemical structure of the polymer heavily influences the glasstransition by affecting mobility.

The Tg can be determined as the approximate midpoint of a temperaturerange over which the glass transition takes place. [ASTM D883-90]. Themost frequently used definition of Tg uses the energy release on heatingin differential scanning calorimetry (DSC). As used herein, the Tgrefers to a glass transition temperature as measured by differentialscanning calorimetry (DSC) at a 20° C./min heating rate.

The “melting temperature” (Tm) is the temperature at which a materialchanges from solid to liquid state. In polymers, Tm is the peaktemperature at which a semicrystalline phase melts into an amorphousstate. Such a melting process usually takes place within a relativenarrow range (<20° C.), thus it is acceptable to report Tm as a singlevalue.

“Elastic deformation” refers to deformation of a body in which theapplied stress is small enough so that the object retains, substantiallyretains, or moves towards its original dimensions once the stress isreleased.

The term “plastic deformation” refers to permanent deformation thatoccurs in a material under stress after elastic limits have beenexceeded.

“Stress” refers to force per unit area, as in the force acting through asmall area within a plane. Stress can be divided into components, normaland parallel to the plane, called normal stress and shear stress,respectively. Tensile stress, for example, is a normal component ofstress applied that leads to expansion (increase in length). Inaddition, compressive stress is a normal component of stress applied tomaterials resulting in their compaction (decrease in length). Stress mayresult in deformation of a material, which refers to a change in length.“Expansion” or “compression” may be defined as the increase or decreasein length of a sample of material when the sample is subjected tostress.

“Strain” refers to the amount of expansion or compression that occurs ina material at a given stress or load. Strain may be expressed as afraction or percentage of the original length, i.e., the change inlength divided by the original length. Strain, therefore, is positivefor expansion and negative for compression.

“Strength” refers to the maximum stress along an axis which a materialwill withstand prior to fracture. The ultimate strength is calculatedfrom the maximum load applied during the test divided by the originalcross-sectional area.

“Modulus” and “stiffness” may be defined as the ratio of a component ofstress or force per unit area applied to a material divided by thestrain along an axis of applied force that results from the appliedforce. The modulus or the stiffness typically is the initial slope of astress—strain curve at low strain in the linear region. For example, amaterial has both a tensile and a compressive modulus.

The tensile stress on a material may be increased until it reaches a“tensile strength” which refers to the maximum tensile stress which amaterial will withstand prior to fracture. The ultimate tensile strengthis calculated from the maximum load applied during a test divided by theoriginal cross-sectional area. Similarly, “compressive strength” is thecapacity of a material to withstand axially directed pushing forces.When the limit of compressive strength is reached, a material iscrushed.

“Elongation at break” is the elongation recorded at the moment ofrupture of a specimen in a tensile elongation test, expressed as apercentage of the original length or the strain.

“Toughness” is the amount of energy absorbed prior to fracture, orequivalently, the amount of work required to fracture a material. Onemeasure of toughness is the area under a stress-strain curve from zerostrain to the strain at fracture. The units of toughness in this caseare in energy per unit volume of material. See, e.g., L. H. Van Vlack,“Elements of Materials Science and Engineering,” pp. 270-271,Addison-Wesley (Reading, Pa., 1989).

While particular embodiments of the present invention have been shownand described, it will be obvious to those skilled in the art thatchanges and modifications can be made without departing from thisinvention in its broader aspects. Therefore, the appended claims are toencompass within their scope all such changes and modifications as fallwithin the true spirit and scope of this invention.

What is claimed is:
 1. A medical device implantable within a peripheralvessel of the body, comprising: a cylindrical radially expandable bodyformed from a polymer formulation comprising a bioresorbable elasticmaterial greater than 60 wt % of the body and a bioresorbable rigidmaterial less than 40 wt % of the body which form rigid domainsdispersed throughout a matrix of the elastic material, wherein acrystallinity of the rigid domains is 10 to 20%; and an anti-restenosisdrug associated with the body for delivery to the vessel uponimplantation of the medical device in the peripheral vessel, wherein theelastic material has a glass transition temperature (Tg)<25 deg C andthe rigid material has a Tg greater than 37 deg C, and wherein the bodyis configured to be expanded from a crimped state to an expanded statewithin the peripheral vessel in contact with the vessel wall.
 2. Thedevice of claim 1, wherein the elastic material comprises elasticpolymer or segments selected from the group consisting ofpoly(4-hydroxybutyrate) (P4HB), polycaprolactone (PCL),poly(trimethylene carbonate) (PTMC), poly(butylene succinate) (PBS), andpoly(p-dioxanone) (PDO).
 3. The device of claim 1, wherein the rigidmaterial comprises rigid polymer or segments selected from the groupconsisting of poly(L-lactide) (PLLA), polyglycolide (PGA) andpoly(L-lactide-co-glycolide) (PLGA).
 4. A medical device implantablewithin a peripheral vessel of the body, comprising: a cylindricalradially expandable body formed from a polymer formulation comprising abioresorbable elastic material greater than 60 wt % of the body and abioresorbable rigid material less than 40 wt % of the body which formrigid domains dispersed throughout a matrix of the elastic material; andan anti-restenosis drug associated with the body for delivery to thevessel upon implantation of the medical device in the peripheral vessel,wherein the elastic material has a glass transition temperature (Tg)<25deg C and the rigid material has a Tg greater than 37 deg C, and whereinthe body is configured to be expanded from a crimped state to anexpanded state within the peripheral vessel in contact with the vesselwall, wherein the polymer formulation is a polymer blend of an elasticpolymer as the elastic material and a block or random copolymerincluding rigid polymer segments as the rigid material and elasticpolymer segments, wherein the elastic polymer of the blend includes PCL,PTMC, PDO, or P4HB, the rigid polymer segments of the copolymer includePLLA or PGA, and the elastic polymer segments of the copolymer includePCL, PTMC, PDO, or P4HB, wherein a number average molecular weight (MW)of the elastic material and the copolymer is 50 to 100 kDa.
 5. Thedevice of claim 1, wherein the polymer formulation is a polymer blend ofan elastic polymer as the elastic material, a rigid polymer as the rigidmaterial, and a block copolymer less than 5 wt % of the body includingelastic polymer segments and rigid polymer segments corresponding to theelastic polymer and the rigid polymer, respectively, which acts ascompatibilizer between the elastic polymer and the rigid polymer,wherein the elastic polymer includes PCL, PTMC, PDO, or P4HB, the rigidpolymer segments of the copolymer include PLLA or PGA.
 6. The device ofclaim 1, wherein the polymer formulation is a polymer blend of anelastic block or random copolymer including elastic polymer segments asthe elastic material and rigid polymer segments and a rigid polymer asthe rigid material, wherein the elastic polymer segments of thecopolymer include PCL, PTMC, PDO, or P4HB, the rigid polymer segments ofthe copolymer include PLLA or PGA, and the rigid polymer includes PLLAor PGA.
 7. The device of claim 1, wherein the polymer formulation is ablock copolymer including an elastic polymer segment as the elasticmaterial and a rigid polymer segment as the rigid material, wherein theelastic polymer segment of the copolymer includes PCL, PTMC, PDO, orP4HB and the rigid polymer segment of the copolymer includes PLLA orPGA.
 8. The device of claim 1, wherein the elastic material has anelongation at break of greater than 50% and modulus of elasticity ofless than 1 GPa.
 9. The device of claim 1, wherein the rigid materialhas an elongation at break of less than 5% and modulus of greater than 3GPa.
 10. The device of claim 1, wherein a radial strength of the deviceis 10 to 150 mm Hg.
 11. The device of claim 1, wherein a crush recoveryof the device is such that the device attains greater than about 80% or90% of its diameter after being crushed to at least 50% of a pre-crushdiameter.
 12. The device of claim 1, wherein the device has an expandeddiameter in an expanded state between 7 and 9 mm.
 13. The device ofclaim 1, wherein when the device is expanded by a balloon to theexpanded diameter, the device plastically deforms.
 14. The device ofclaim 1, wherein when the device expands to the expanded diameter, thedevice self-expands and deforms elastically.
 15. The device of claim 1,wherein the anti-restenosis drug comprises an anti-proliferative drug,anti-inflammatory drug, or both.
 16. The device of claim 1, wherein aradial strength of the device in an expanded state is at most a radialpressure for the device to maintain contact with the vessel wall.